Related Experiment Video

Updated: Oct 16, 2026

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

The antiarrhythmic potential of angiotensin II antagonism: experience with losartan

I Gavras1, H Gavras

  • 1Department of Medicine, Boston University School of Medicine, Massachusetts 02118, USA.

American Journal of Hypertension
|May 29, 2000
PubMed

Insights

Inhibition of the renin-angiotensin system, particularly with angiotensin II receptor blockers like losartan, offers significant protection against heart disease and arrhythmias. This approach reduces mortality and sudden cardiac death in patients with heart failure.

Area of Science:

  • Cardiology
  • Pharmacology
  • Nephrology

Background:

  • Renin-angiotensin system (RAS) inhibition is established for protecting organs from hypertension.
  • Angiotensin-converting enzyme (ACE) inhibitors reduce morbidity and mortality in ischemic heart disease and heart failure.
  • ACE inhibitors may decrease sudden deaths by reducing complex arrhythmias.

Purpose of the Study:

  • To review the arrhythmogenic properties of angiotensin II.
  • To explore the antiarrhythmic potential of losartan, an angiotensin II type 1 receptor antagonist.
  • To discuss the pharmacologic mechanisms underlying losartan's antiarrhythmic effects.

Main Methods:

  • Literature review of studies on RAS inhibition and cardiovascular outcomes.
  • Analysis of clinical trial data comparing ACE inhibitors and angiotensin II receptor antagonists.
  • Examination of preclinical and clinical evidence on angiotensin II's role in cardiac arrhythmias.

Main Results:

  • Losartan demonstrated a 46% mortality reduction compared to captopril in elderly heart failure patients.
  • Evidence suggests angiotensin II contributes to cardiac arrhythmogenesis.
  • Losartan exhibits antiarrhythmic properties, potentially through blocking angiotensin II type 1 receptors.

Conclusions:

  • Inhibition of the renin-angiotensin system, including with angiotensin II receptor antagonists like losartan, is crucial for managing hypertensive complications.
  • Losartan shows promise in reducing mortality and potentially preventing sudden cardiac death in heart failure patients.
  • Understanding the mechanisms of angiotensin II's arrhythmogenic effects can guide the development of novel antiarrhythmic therapies.

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...